Journal of Alzheimers Disease & Parkinsonism
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 4334
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Rivastigmine and Citalopram treatment for Alzheimer′s disease (AD) in daily clinical practice
5th International Conference on Alzheimer芒鈧劉s Disease & Dementia
Krishna Prasad Pathak
Amity Global Education, Nepal
ScientificTracks Abstracts: J Alzheimers Dis Parkinsonism
DOI:
Abstract
Background: Pharmacological treatment for AD and depression are unfortunately few and of limited efficacy to cure the disease. Objectives: To assess the combined effects of rivastigmine and citalopram on Alzheimer's Disease. Methods: Longitudinal clinical prospective study with 1278 AD patients on rivastigmine 9,5mg/patch and citalopram 20-40 mg/day over 48 months was assessed on the basis of DSM-IV, NINCDS-ADRDA, MMSE, FRSSD, GDS, HRS-D and follow up of the patients. Results: Four years after the baseline assessment, there were no significant differences in MMSE, Geriatric depression scale and Hamilton rating scale for depression between patients treated with rivastigmine alone or combined rivastigmine with citalopram with or without depression (p>0.05). Functional Rating Scale for symptoms of dementia, Activities of Daily Living of patients with AD and depression treated with rivastigmine was significantly worse than patients treated with rivastigmine and no depression (p=0.027). Conclusions: The combination of rivastigmine and citalopram had no better results than rivastigmine alone in patients with AD.Biography
Krishna prasad pathak has completed PhD at the age of 35 years from Macedoniya university and doing research work on demenita issue in Nepal. He is the lecturer of Amity Global education , kathmandu Nepal. He has published some papers in reputed journals and has been serving as an editorial board member.
Email: pathakrishna37@gmail.com
